natgillin/translations-raw huggingface dataset:
One controlled clinical trial with Betaferon in patients with relapsing-remitting multiple sclerosis and able to walk unaided (baseline EDSS 0 to 5.5) was performed.
Provedeno je jedno kontrolirano kliničko ispitivanje s lijekom Betaferon u bolesnika s relapsno-remitirajućom multiplom sklerozom koji hodaju samostalno (početne vrijednosti na EDSS ljestvici od 0 do 5,5).
One controlled clinical trial with Extavia was performed in patients with a single clinical event and Magnetic Resonance Imaging (MRI) features suggestive of multiple sclerosis (at least two clinically silent lesions on the T2-weighted MRI).
Jedno je kontrolirano kliničko ispitivanje s Extavijom provedeno u bolesnika s jednim kliničkim događajem i karakteristikama na snimci napravljenoj magnetskom rezonancijom (MR) koje upućuju na multiplu sklerozu (najmanje dvije klinički tihe lezije na T2 mjerenoj snimci MR-om).
One cotton ball or gauze
Jedan komadić vate ili gaze
One cutaneous patch
Jedan flaster za kožu
One device pack containing:
Jedno pakiranje s priborom za primjenu sadrži:
One dose (0.2 ml) contains:
Jedna doza od ( 0,2) ml:
One dose (0.5 ml of the reconstituted vaccine) contains: (Originally contained in the powder)
Jedna doza (0,5 ml rekonstituiranog cjepiva) sadrži: (Izvorno sadržan u prašku)
One dose (0.5 ml of the reconstituted vaccine) contains: The active substances are:
Jedna doza (0,5 ml pripremljenog cjepiva) sadrži: Djelatne tvari su:
One dose (0.5 ml) contains: Active Ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in eggs, and adjuvanted with MF59C.1, of strain:
Jedna doza (0,5 ml) sadrži: Djelatni sastojci: Površinski antigeni virusa influence (hemaglutinin i neuraminidaza), umnoženi na jajima i adjuvantirani s MF59C.1, soja:
One dose (0.5 ml) contains: Active substances:
Jedna doza (0,5 ml) sadrži: Djelatne tvari:
One dose (1 ml) contains:
Jedna doza (1 ml) sadržava:
One dose (2 ml) contains rotavirus type*:
Jedna doza (2 ml) sadrži rotavirus serotipa*:
One dose (2 ml) contains:
Svaka doza (2 ml) sadrži:
One dose (2 ml) of reconstituted emulsion containing  105.2 CCID50 of live attenuated Aujeszky’s disease virus strain NIA3-783 for each pig.
Jedna doza (2 ml) rekonstituirane emulzije koja sadrži ≥ 105,2 CCID50 živog, atenuiranog virusa bolesti Aujeszkoga soja NIA3-783 za svaku svinju.
One dose consists of 1 vial of MenA Lyophilised Conjugate Component to be reconstituted with 1 vial of MenCWY Liquid Conjugate Component.
Jedna doza sadrži 1 bočicu liofiliziranog MenA konjugata za rekonstituciju s 1 bočicom tekućeg MenCWY konjugata.
One dose contains:
Jedna doza sadrži:
One dose is
Jedna doza je
One dose of 0.5 ml contains: Active Ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in eggs, and adjuvanted with MF59C.1, of strain:
Jedna doza od 0,5 ml sadrži: Djelatni sastojci: površinski antigeni virusa influence (hemaglutinin i neuraminidaza), umnoženi na jajima i adjuvantirani s MF59C.1, soja:
One dose of 0.5 ml contains: Active Ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in eggs, of strain:
Jedna doza od 0,5 ml sadrži: Djelatni sastojci: površinski antigeni virusa influence (hemaglutinin i neuraminidaza), umnoženi na jajima, soja:
One dose of 0.5 ml contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in eggs, of strain:
Jedna doza od 0,5 ml sadrži: površinski antigeni virusa influence (hemaglutinin i neuraminidaza), umnoženi na jajima, soja:
One dose of 2 ml contains:
Jedna doza od 2 ml sadrži
One dose of 2 ml contains:
Svaka doza od 2 ml sadrži:
One dose of 2 ml of vaccine contains:
Jedna doza od 2 ml cjepiva sadrži:
One dose of 2 ml: Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02
Jedna doza od 2 ml: inaktivirani virus plavog jezika, serotip 8, soj BTV-8/BEL2006/02
One dose of 30 l to be administered by eye drop.
Jednu dozu od 30l primijeniti kao kap u oko.
One dose of 30l should be administered by eye drop.
Jednu dozu od 30l primijeniti kao kap u oko.
One dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 administered after one or two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004
Jedna doza AS03-adjuvantiranog cjepiva i 3,75 µg hemaglutinina dobivenog iz soja A/Indonesia/05/2005, primijenjena nakon jedne ili dvije doze AS03-adjuvantiranog cjepiva koje sadrži 3,75 µg hemaglutinina dobivenog iz soja A/Vietnam/1194/2004
One dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 manufactured using a different process administered after one or two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 manufactured using a different process
Jedna doza cjepiva s adjuvansom AS03 i 3,75 µg HA dobivenog iz soja A/Indonesia/05/2005, proizvedenog različitim postupkom proizvodnje, primijenjena nakon jedne ili dvije doze cjepiva s adjuvansom AS03 i 3,75 µg HA dobivenog iz soja A/Vietnam/1194/2004 proizvedenog različitim postupkom proizvodnje
One dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Turkey/Turkey/1/2005 administered after two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from Indonesia/5/2005
Jedna doza cjepiva s adjuvansom AS03 i 3,75 µg HA dobivenog iz soja A/Turkey/Turkey/1/2005 primijenjena nakon dvije doze cjepiva s adjuvansom AS03 koje sadrži 3,75 µg HA dobivenog iz soja Indonesia/5/2005
One dose of PecFent may include administration of 1 spray (100 microgram or 400 microgram doses) or 2 sprays (200 microgram or 800 microgram doses) of the same strength (either 100 microgram or 400 microgram strength).
Jedna doza lijeka PecFent može uključivati primjenu 1 potiska spreja (doza od 100 mikrograma ili 400 mikrograma) ili 2 potiska spreja (doza od 200 mikrograma ili 800 mikrograma) iste jačine (jačina ili 100 mikrograma ili 400 mikrograma).
One dose of Provenge contains a minimum of 50 x 106 autologous CD54+ cells activated with PAP-GM-CSF, suspended in 250 mL of Lactated Ringer’s Injection, in a sealed, patient-specific polyolefin bag.
Jedna doza lijeka Provenge sadrži najmanje 50 x 106 autolognih CD54+ stanica aktiviranih PAP-GM- CSF-om, suspendiranih u 250 mL Ringerove otopine s laktatom, u zatvorenoj, poliolefinskoj vrećici posebno označenoj za svakog bolesnika.
One dose should be given yearly.
Ponovljenim davanjem jedne doze svake godine.
One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide
Jedan odmjerni korak sadrži 1 jedinicu degludek inzulina i 0,036 mg liraglutida.
One dose, of 0.2 ml of reconstituted vaccine at least 72 hours prior to period of anticipated risk.
Jedna doza od 0,2 ml rekonstituiranog cjepiva najkasnije 72 sata prije rizika od kontakta sa uzročnikom.
One dose, of 0.2 ml of reconstituted vaccine at least 72 hours prior to period of anticipated risk.
Jedna doza od 0,2 ml rekonstituiranog cjepiva, najkasnije 72 sata prije rizika od kontakta sa uzročnikom.
One dose1 (0.5 ml) contains:
Jedna doza1 (0,5 ml) sadrži:
One drop containing one dose should be applied into one nostril or one eye.
Jedna kap koja sadrži jednu dozu mora se primijeniti u jednu nosnicu ili jedno oko.
One drop in the affected eye or eyes, once a day-in the evening.
Jedna kap u oko (ili oči) koje se liječi, jednom dnevno - navečer.
One drop in the affected eye or eyes, once a day-in the morning or in the evening.
Jedna kap u oko (oči) koje se liječi, jednom dnevno-ujutro ili navečer.
One drop in the affected eye or eyes, once a day.
Jedna kap u zahvaćeno oko ili oči, jedanput na dan.
one drop in the affected eye or eyes, twice a day.
jedna kap u oko ili oči koje se liječe dvaput na dan.
One emergency kit contains 10 vials of Savene powder and 3 bottles of Savene diluent
Set za hitne slučajeve sadrži 10 bočica praška Savene i 3 boce otapala lijeka Savene.
One Enurev Breezhaler pack contains: one Enurev Breezhaler inhaler one or more blisters, each containing either 6 or 10 Enurev Breezhaler capsules to be used in the inhaler.
Jedno Enurev Breezhaler pakiranje sadrži: jedan Enurev Breezhaler inhalator jedan ili više blistera, svaki sadrži 6 ili 10 Enurev Breezhaler kapsula koje se koriste u inhalatoru.
One event (angioedema) was considered serious and life-threatening, and the patient was discontinued from study treatment.
Jedna se nuspojava (angioedem) smatrala ozbiljnom i opasnom po život te je taj bolesnik isključen iz ispitivanja.
One event was Grade 3; the remainder was Grade 2.
Jedan događaj bio je 3. stupnja, ostali su bili 2.stupnja.
One field study involved 485 dogs with flea and/or tick infestations that were treated once either with Vectra 3D or another spot-on product containing two other substances that control fleas and ticks, fipronil and (s)-methoprene.
Jedno terensko ispitivanje uključivalo je 485 pasa s infestacijama buhama i/ili krpeljima koji su tretirani jednom s VMP-om Vectra 3D ili drugim VMP-om za nakapavanje koji sadrži dvije druge tvari za kontrolu buha i krpelja, fipronilom i (s)-metoprenom.
One film-coated tablet contains 100 mg erlotinib (as erlotinib hydrochloride).
Jedna filmom obložena tableta sadrži 100 mg erlotiniba (u obliku erlotinibklorida).
One film-coated tablet contains 150 mg erlotinib (as erlotinib hydrochloride).
Jedna filmom obložena tableta sadrži 150 mg erlotiniba (u obliku erlotinibklorida).
One film-coated tablet contains 20 mg afatinib (as dimaleate).
Jedna filmom obložena tableta sadrži 20 mg afatiniba (u obliku afatinibdimaleata).
One film-coated tablet contains 20 mg of leflunomide
Jedna filmom obložena tableta sadrži 20 mg leflunomida.
One film-coated tablet contains 25 mg erlotinib (as erlotinib hydrochloride).
Jedna filmom obložena tableta sadrži 25 mg erlotiniba (u obliku erlotinibklorida).
One film-coated tablet contains 30 mg afatinib (as dimaleate).
Jedna filmom obložena tableta sadrži 30 mg afatiniba (u obliku afatinibdimaleata).
One film-coated tablet contains 40 mg afatinib (as dimaleate).
Jedna filmom obložena tableta sadrži 40 mg afatiniba (u obliku afatinibdimaleata).
One film-coated tablet contains 5 mg ivabradine (equivalent to 5.39 mg ivabradine as hydrochloride)
Jedna filmom obložena tableta sadrži 5mg ivabradina (što odgovara 5,39 mg ivabradinklorida)
One film-coated tablet contains 50 mg afatinib (as dimaleate).
Jedna filmom obložena tableta sadrži 50 mg afatiniba (u obliku afatinibdimaleata).
One film-coated tablet contains 50 mg of the active substance delamanid.
Jedna filmom obložena tableta sadrži 50 mg djelatne tvari delamanida.
One film-coated tablet contains 500 mg of saquinavir as saquinavir mesilate.
Jedna filmom obložena tableta sadrži 500 mg sakvinavira u obliku sakvinavirmesilata.
One film-coated tablet contains 7.5 mg ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride).
Jedna filmom obložena tableta sadrži 7,5 mg ivabradina (što odgovara 8,085 mg ivabradinklorida).
One Firazyr-treated patient tested positive for anti-icatibant antibodies before and after treatment with Firazyr.
Jedan bolesnik liječen Firazyrom na testu je bio pozitivan na anti-ikatibant protutijela prije i nakon liječenja Firazyrom.
One further change was seen which was not statistically significant (p > 0.05), but which did show a significant dose trend.
Primijećena je još jedna promjena koja nije bila statistički značajna (p  0,05), ali koja je pokazala značajnu ovisnost o dozi.
One further change was seen which was not statistically significant (p  0.05), but which did show a significant dose trend.
Primijećena je još jedna promjena koja nije bila statistički značajna (p  0,05), ali koja je pokazala značajnu ovisnost o dozi.
One further injection must be given, at least 2 weeks before farrowing.
Još jedna injekcija se mora dati najmanje 2 tjedna prije prasenja.
One g gel contains 78 mg of 5-aminolaevulinic acid (as hydrochloride).
Jedan g gela sadrži 78 mg 5-aminolevulinatne kiseline (u obliku klorida).
One GIST patient was enrolled at the 15 mg/m2 dose level with no evidence of benefit.
Jedan bolesnik s GIST-om uključen je u ispitivanje pri razini doze od 15 mg/m2 bez dokaza o koristi.
One glass vial containing Cayston is opened by tearing and flipping up the blue cap or lifting up the metal flap, the metal ring is removed by carefully pulling the flap (tweezers or small pliers may be used to remove the metal ring if necessary) and the grey rubber stopper removed.
Jedna staklena bočica koja sadrži Cayston otvara se tako da se najprije pokida i podigne plavi zatvarač ili podigne metalni jezičac, zatim se opreznim povlačenjem jezičca skida metalni prsten (po potrebi se za njegovo skidanje mogu koristiti pinceta ili mala kliješta), a potom se skida sivi gumeni čep.
one glass vial of recombinant human hyaluronidase, and one glass vial of human normal immunoglobulin 10%.
jednu staklenu bočicu rekombinantne ljudske hijaluronidaze i jednu staklenu bočicu normalnog ljudskog imunoglobulina 10%.
One graduation mark of syrup contains 0.31 mmol (or 7.09 mg) sodium.
Jedna odmjerna oznaka sirupa sadrži 0,31 mmol (ili 7,09 mg) natrija.
One gram (g) gel contains 78 mg of 5-aminolaevulinic acid (as hydrochloride).
Jedan gram (g) gela sadrži 78 mg 5-aminolevulinatne kiseline (u obliku klorida).
One gram of gel contains 1 mg methylparahydroxybenzoate (E218) and 55 mg propylene glycol.
Jedan gram gela sadrži 1 mg metilparahidroksibenzoata (E218) i 55 mg propilenglikola.
One gram of gel contains 3.3 mg of brimonidine.
Jedan gram gela sadrži 3,3 mg brimonidina.
one hand, pick up the open ampoule, insert the needle and draw up all of the solvent.
podignite otvorenu ampulu, umetnite iglu i uvucite svo otapalo.
One hard capsule contains 0.5 mg anagrelide (as anagrelide hydrochloride).
Jedna tvrda kapsula sadrži 0,5 mg anagrelida (u obliku anagrelidklorida).
One hard capsule contains 117.08 mg lactose (as monohydrate).
Jedna tvrda kapsula sadrži 117,08 mg laktoze (u obliku laktoze hidrata).
One hard capsule contains 156.11 mg lactose (as monohydrate).
Jedna tvrda kapsula sadrži 156,11 mg laktoze (u obliku laktoze hidrata).
One hard capsule contains cabozantinib (S)-malate equivalent to 20 mg cabozantinib.
Jedna tvrda kapsula sadrži kabozantinib (S)-malat u količini koja odgovara 20 mg kabozantiniba.
One HDPE bottle with child resistant closure and sealing disk, containing 30 tablets and one silica gel desiccant sachet, packed within a cardbox.
Jedna HDPE boca sa sigurnosnim zatvaračem za djecu i zapornim diskom koja sadrži 30 tableta i jednu vrećicu silikagela kao sredstvo za sušenje zapakiranu unutar kartonske kutije.
one human insulin preparation to another, a regimen with only regular insulin to one with a longer-acting insulin.
jednog pripravka humanog inzulina na drugi, s režima doziranja u kojem se primjenjuje samo običan inzulin na režim u kojem se primjenjuje inzulin s duljim djelovanjem.
One hundred and eighteen (14%) enzalutamide-treated patients and 321 (40%) of placebo-treated patients had an event.
118 (14%) bolesnika liječenih enzulatamidom i 321 (40%) bolesnik liječen placebom imali su događaj.
One hundred and five patients were randomised to 5-FU/FA + placebo arm and 104 patients to 5-FU/FA + Avastin (5 mg/kg every 2 weeks) arm.
Randomizirano je 105 bolesnika u skupinu 5-FU/FA + placebo, a 104 bolesnika u skupinu 5-FU/FA + Avastin (5 mg/kg svaka 2 tjedna).
One hundred and four (20%) of the 511 patients experienced ≥Grade 3 infections.
Stotinu i četiri (20%) od 511 bolesnika imala su infekcije ≥ 3. stupnja.
One hundred and ninety had at least 1 evaluable time point response and were included in the analysis (table 3).
Sto devedeset bolesnika je imalo procjenjiv odgovor u barem jednoj vremenskoj točki i bili su uključeni u analizu (tablica 3).
One hundred and six patients received at least one 50 mg dose of sunitinib on schedule 4/2.
106 bolesnika je dobilo najmanje jednu dozu od 50 mg sunitiniba prema shemi 4/2.
One hundred and twenty (70%) patients in the chemotherapy arm received subsequent crizotinib treatment.
Sto dvadeset (70%) bolesnika u skupini koja je primala kemoterapiju primilo je nakon toga liječenje krizotinibom.
One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114 rheumatoid arthritis patients treated in clinical trials with etanercept for up to approximately 6 years, including 231 patients treated with etanercept in combination with methotrexate in the 2-year active- controlled study.
Sto dvadeset devet (129) novih zloćudnih bolesti različitih vrsta zabilježeno je u 4114 bolesnika s reumatoidnim artritisom liječenih etanerceptom u razdoblju do približno 6 godina u kliničkim ispitivanjima, uključujući 231 bolesnika liječenog etanerceptom u kombinaciji s metotreksatom u dvogodišnjem ispitivanju s aktivnom kontrolom.
One hundred eighty six patients were randomized to receive docetaxel (100 mg/m2) with or without trastuzumab; 60% of patients received prior anthracycline-based adjuvant chemotherapy.
Randomizirano je 186 bolesnika koji su primali docetaksel (100 mg/m2) s trastuzumabom ili bez trastuzumaba, a 60% bolesnika ranije je primalo adjuvantnu terapiju temeljenu na antraciklinima.
One hundred forty-one and 139 adult subjects were randomised to a tenofovir disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate treatment arm, respectively.
Stotinu četrdeset jedan i 139 odraslih ispitanika bili su randomizirani u skupinu koja je bila liječena tenofovirdizoproksilfumaratom, odnosno u skupinu koja je bila liječena emtricitabinom i tenofovirdizoproksilfumaratom.
One hundred patients then entered the second part of the study, which compared Ilaris with placebo.
Zatim je stotinu bolesnika uključeno u drugi dio ispitivanja, koje je usporedilo lijek Ilaris s placebom.
One hundred patients were originally treated with Kaletra in the study (including 51 patients receiving 400/100 mg twice daily and 49 patients at either 200/100 mg twice daily or 400/200 mg twice daily).
U početku studije ukupno je 100 bolesnika liječeno lijekom Kaletra (51 bolesnik primao je 400/100 mg dva puta dnevno, a 49 bolesnika primalo je 200/100 mg dva puta dnevno ili 400/200 mg dva puta dnevno).
One hundred patients were originally treated with Kaletra in the study (including 51 patients receiving 400/100 mg twice daily and 49 patients at either 200/100 mg twice daily or 400/200 mg twice daily).
U početku studije ukupno je 100 bolesnika liječeno lijekom Kaletra (51 bolesnik primao je 400/100 mg dva puta dnevno, a 49 bolesnika primalo je 200/100 mg dva puta dnevno ili 400/200 mg dva puta dnevno.
One Hypodermic syringe and safety needle (Hypodermic Device)
Jednu hipodermalnu štrcaljku i zaštićenu iglu (hipodermalna naprava)
One ibritumomab tiuxetan glass vial, with 2 ml clear, colourless solution.
jednu staklenu bočicu ibritumomab tiuksetana s 2 ml bistre, bezbojne otopine
One Ilaris injection kit contains 1 vial of powder for solution for injection, 1 vial of solvent,1 injection syringe of 1 ml, 1 safety needle, 2 vial adapters and 4 cleansing swabs.
Jedan Ilaris komplet za injekciju sadrži 1 bočicu praška za otopinu za injekciju, 1 bočicu otapala, 1 štrcaljku za injekciju od 1 ml, 1 sigurnosnu iglu, 2 nastavka za bočicu i 4 tupfera za čišćenje.
One implant preloaded in one implanter
Jedan implantat smješten u jednom implantatoru.
One implant preloaded in one implanter.
Jedan implantat pakovan u jednom implantatoru.
One implant should be administered subcutaneously between the shoulder blades of the dog.
Subkutano aplicirati jedan implantat između lopatica.
One individual blister should be teared off from the blister card along the perforated line.
Pojedini blister je po perforaciji potrebno otkinuti od blister pločice.
One inhalation of Relvar Ellipta 184/22 micrograms once daily.
Jedna inhalacija lijeka Relvar Ellipta od 184/22 mikrograma jedanput na dan.
One inhalation of Relvar Ellipta 92/22 micrograms once daily.
Jedna inhalacija lijeka Relvar Ellipta od 92/22 mikrograma jedanput na dan.
One inhalation of Revinty Ellipta 184/22 micrograms once daily.
Jedna inhalacija lijeka Revinty Ellipta od 184/22 mikrograma jedanput na dan.
One inhalation of Revinty Ellipta 92/22 micrograms once daily.
Jedna inhalacija lijeka Revinty Ellipta od 92/22 mikrograma jedanput na dan.
One inhalation session will usually last about 4 to 10 minutes with I-Neb AAD depending on the prescribed dose.
Jedna inhalacija obično traje između 4 i 10 minuta s uređajem I-Neb AAD , ovisno o propisanoj dozi.
One inhalation twice a day
Jedan udah dvaput na dan
One initiation dose pack of Bronchitol contains 1 blister with 10 capsules and 1 inhaler.
Jedno pakovanje Bronchitola za početnu dozu sadrži 1 blister s 10 kapsula i 1 inhalator.
One injection at each gestation, at least 2 to 4 weeks before farrowing.
Jednu injekcija dati u svakom graviditetu, najmanje 2 do 4 tjedna prije prasenja.
One injection at each gestation, at least 2 to 4 weeks before farrowing.
Jednu injekciju dati u svakom graviditetu, najmanje 2 do 4 tjedna prije prasenja.
One injection from 3 weeks of age.
Jedna injekcija u dobi od 3 tjedna.
One injection is usually enough to treat an attack, but a second injection may be given if the patient does not improve enough after the first one.
Jedna injekcija obično je dovoljna za terapiju napadaja, no druga se injekcija može dati ako se stanje bolesnika nakon prve injekcije ne poboljša dovoljno.
One injection of Avonex, once a week.
Jedna injekcija Avonexa, jednom tjedno
One injection of Avonex, once a week.
Jedna injekcija Avonexa, jednom tjedno.
One injection using Avonex Pen, once a week.
Jedna injekcija koristeći Avonex Pen, jednom tjedno.
One injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep).
Jedna injekcija: od 1 mjeseca starosti (ili od 2,5 mjeseca starosti u mladih životinja rođenih imunim ovcama).
One International Unit (IU) of factor IX activity is equivalent to that quantity of factor IX in one ml of normal human plasma.
Jedna internacionalna jedinica (IU) aktivnosti faktora IX odgovara količini faktora IX u jednom ml normalne ljudske plazme.
One International Unit (IU) of factor IX activity is equivalent to that quantity of factor IX in one ml of normal human plasma.
Jedna internacionalna jedinica (IU) aktivnosti IX faktora IX odgovara količini faktora IX u jednom ml normalne ljudske plazme.
One International Unit (IU) of factor IX activity is related to the quantity of factor IX in the International Standard for factor II, VII, IX and X in human plasma (approved by the WHO) which approximates to the quantity of factor IX in one ml of normal human plasma.
Jedna internacionalna jedinica (IU) aktivnosti faktora IX odnosi se na količinu faktora IX prema Međunarodnom standardu za faktore II, VII, IX i X u ljudskoj plazmi (odobrenom od SZO), koja odgovara količini faktora IX u jednom ml normalne ljudske plazme.
One intravenous injection of 4200 U (two vials).
Jedna intravenska injekcija od 4200 U (dvije bočice).
One intravenous injection of 50 U/kg body weight.
Jedna intravenska injekcija od 50 U/kg tjelesne težine.
One involves mutations in ribosomal protein L3, the second is a non-specific efflux mechanism (ABC transporter vgaAv).
Jedan uključuje mutaciju ribosomskog proteina L3, drugi je nespecifični mehanizam efluksa (ABC transporter vgaAv).
one is given as an infusion into a vein (intravenous infusion) the other is given as an injection under the skin (subcutaneous injection) using a manual syringe or the administration system.
jedan koji se daje putem infuzije u venu (intravenskom infuzijom) drugi koji se daje putem injekcije pod kožu (supkutanom injekcijom) uz pomoć štrcaljke ili sustava za primjenu.
one is given as an infusion into a vein (intravenous infusion) the other is given as an injection under the skin (subcutaneous injection).
jedan koji se daje putem infuzije u venu (intravenskom infuzijom) drugi koji se daje putem injekcije pod kožu (supkutanom injekcijom).
one is given as an infusion into a vein over 30 to 90 minutes the other is given as a subcutaneous injection over 2 to 5 minutes.
jedan se primjenjuje u venu tijekom 30 do 90 minuta, drugi se primjenjuje injekcijom pod kožu tijekom 2 do 5 minuta.